VEGFA and glioblastoma: Yet, treatment with the monoclonal antibody bevacizumab targeting the pivotal proangiogenic factor vascular endothelial growth factor (VEGF) has not improved overall survival of glioblastoma patients in recurrent (Wick et al. 2017) or newly diagnosed glioblastoma (Chinot et al. 2014; Gilbert et al. 2014) or on a population level (Gramatzki et al. 2018).